Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.

ABSTRACT:

Background

A recent randomized-withdrawal, active- and placebo-controlled, double-blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour-related pain in patients who were opioid naive or dissatisfied with current treatment (Pain Physician, 2014, 17, 329-343). This post hoc, subgroup analysis evaluated the efficacy and tolerability of tapentadol PR in patients who previously received and were dissatisfied with tramadol for any reason and who had a pain intensity ≥5 (11-point numerical rating scale) before converting directly to tapentadol PR.

Methods

In the original study, eligible patients had been randomized (2:1) and titrated to their optimal dose of tapentadol PR (100-250

SUBMITTER: Kress HG 

PROVIDER: S-EPMC5071659 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature